🔎 Trials Near Me

Home › Cancro alla prostata › Texas › Dallas

Studi clinici su Cancro alla prostata a Dallas, TX

36 studi su Cancro alla prostata cercano partecipanti presso sedi a Dallas e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.

Testo ufficiale dello studio (inglese)

Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

In reclutamentoFase 1/2
  • UT Southwest Simmons Cancer Center, Dallas
Età 12 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT04585750

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

In reclutamentoFase 3
  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Età 18 e oltre · Uomini · Aggiornato il 2 ott 2026 · NCT06931340

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

In reclutamentoFase 2
  • Parkland Memorial Hospital, Dallas
  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06632977

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

In reclutamentoFase 2
  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT03866382

DESTINY-PANTUMOUR04

In reclutamentoStudio osservazionale
  • Research Site, Dallas
Età da 18 a 130 · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07124000

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

In reclutamentoFase 3
  • Texas Oncology - DFW ( Site 8001), Dallas
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06136650

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

In reclutamentoFase 3
  • University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
  • University of Texas Southwestern Medical Center - William P. Clements, Jr., University Hospital, Dallas
  • University of Texas Southwestern Simmons Cancer Center - Redbird, Dallas
  • e altri 2
Età 18 e oltre · Uomini · Aggiornato il 24 set 2026 · NCT07028853

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

In reclutamentoFase 1
  • Mary Crowley Cancer Research, Dallas
Età 18 e oltre · Uomini · Aggiornato il 22 set 2026 · NCT07570979

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

In reclutamentoFase 1
  • Texas Oncology - DFW (Sammons CC), Dallas
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07114601

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

In reclutamentoFase 3
  • University of Texas Southwestern Medical Center, Dallas
Età 18 e oltre · Uomini · Aggiornato il 22 set 2026 · NCT07213674

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

In reclutamentoFase 3
  • Parkland Health & Hospital System ( Site 0069), Dallas
  • UT Southwestern Medical Center ( Site 0039), Dallas
Età 18 e oltre · Uomini · Aggiornato il 17 set 2026 · NCT06925737

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

In reclutamentoFase 3
  • Urology Clinics of North Texas, Dallas
  • University of Texas Southwestern Medical Center, Dallas
Età 18 e oltre · Uomini · Aggiornato il 11 set 2026 · NCT06056830

Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer

In reclutamentoFase 1
  • SCRI at Mary Crowley, Dallas
Età 18 e oltre · Uomini · Aggiornato il 3 set 2026 · NCT07545811

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

In reclutamentoFase 3
  • Urology Clinics Of North Texas, Dallas
Età 18 e oltre · Uomini · Aggiornato il 3 set 2026 · NCT07723248

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

In reclutamentoFase 2
  • University of Texas Southwestern Medical Center, Dallas
Età 18 e oltre · Uomini · Aggiornato il 31 ago 2026 · NCT05726292

A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

In reclutamentoFase 1/2
  • University of Texas Southwestern Medical Center, Dallas
Età 18 e oltre · Uomini · Aggiornato il 20 ago 2026 · NCT06785636

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

In reclutamentoFase 3
  • Parkland Memorial Hospital, Dallas
  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Età 18 e oltre · Uomini · Aggiornato il 19 ago 2026 · NCT04423211

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

In reclutamentoFase 2
  • University of Texas Southwestern Medical Center, Dallas
Età 18 e oltre · Uomini · Aggiornato il 17 ago 2026 · NCT06842498

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

In reclutamentoFase 1
  • Mary Crowley Cancer Research, Dallas
  • University of Texas Southwestern Medical Center, Dallas
Età da 18 a 100 · Uomini · Aggiornato il 13 ago 2026 · NCT05519449

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

In reclutamentoFase 3
  • Dallas VA Medical Center, Dallas
Età 18 e oltre · Uomini · Aggiornato il 14 lug 2026 · NCT06592924

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

In reclutamentoFase 1
  • Urology Clinics of North Texas, Dallas
Età 18 e oltre · Uomini · Aggiornato il 9 lug 2026 · NCT05413421

Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)

In reclutamentoFase 2
  • UT Southwestern Medical Center-Dallas, Dallas
Età 18 e oltre · Uomini · Aggiornato il 30 giu 2026 · NCT07313241

Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance

In reclutamentoFase 3
  • UT Southwestern Medical Center, Dallas
Età da 40 a 89 · Uomini · Aggiornato il 15 giu 2026 · NCT03769766

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

In reclutamentoFase 4
  • Univ of Texas Southwest Med Center, Dallas
Età da 18 a 100 · Uomini · Aggiornato il 4 giu 2026 · NCT05803941

Outcomes of Focal Ablation for Prostate Cancer

In reclutamentoStudio osservazionale
  • UTSW, Dallas
Età da 18 a 90 · Uomini · Aggiornato il 17 apr 2026 · NCT05478694

Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy

In reclutamentoFase 3
  • UT Southwestern Medical Center, Dallas
Età da 30 a 80 · Uomini · Aggiornato il 30 mar 2026 · NCT02064673

Study of AZD0754 in Participants With Metastatic Prostate Cancer

In reclutamentoFase 1/2
  • Research Site, Dallas
Età da 18 a 130 · Uomini · Aggiornato il 23 feb 2026 · NCT06267729

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

In reclutamentoFase 1
  • Mary Crowley Cancer Research, Dallas
  • Baylor University Medical Center, Dallas
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 feb 2026 · NCT06778863

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

In reclutamentoFase 1
  • Urology Clinics of North Texas, Dallas
Età 18 e oltre · Uomini · Aggiornato il 4 feb 2026 · NCT04729114

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

In reclutamentoFase 4
  • UT Southwestern Medical Center, Dallas
Età da 18 a 64 · Tutti i sessi · Aggiornato il 22 gen 2026 · NCT04373564

Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1

In reclutamentoStudio osservazionale
  • Ut Southwestern Medical Center, Dallas
Tutte le età · Uomini · Aggiornato il 12 gen 2026 · NCT06353321

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

In reclutamentoFase 1/2
  • Research Site 120, Dallas
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 nov 2025 · NCT05914116

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

In reclutamentoStudio osservazionale
  • Massive Bio SYNERGY-AI site, Dallas
Tutte le età · Tutti i sessi · Aggiornato il 28 ott 2025 · NCT03452774

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

In reclutamentoFase 3
  • Parkland Memorial Hospital, Dallas
  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Età 18 e oltre · Uomini · Aggiornato il 11 set 2025 · NCT03678025

Customized TULSA-PRO Ablation Registry

In reclutamentoStudio osservazionale
  • University of Texas Southwestern Medical Center, Dallas
Età 18 e oltre · Uomini · Aggiornato il 6 nov 2024 · NCT05001477

Studi su Cancro alla prostata in altre città

Altri studi a Dallas

Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.